More evidence that beta blockers help stop cancers from spreading

US researchers have taken a step forward in understanding how beta blockers may slow the spread of cancer. US researchers have taken a step forward in understanding how beta blockers may slow the spread of cancer.

30 January 2013

• Health & Medicine

Inherited gene fault influences breast cancer survival

Researchers have shown that an inherited gene fault influences the chances of some women surviving breast cancer. It also increases the risk of women developing a second breast cancer. The research is published in this week's Journal of Clinical Oncology. Researchers have shown that an inherited gene fault influences the chances of some women surviving breast cancer. It also increases the risk of women developing a second breast cancer. The research is published in this week's Journal of Clinical Oncology.

11 December 2012

• Health & Medicine

Study confirms fewer, bigger doses of radiotherapy benefit breast cancer patients

A lower total dose of radiotherapy, delivered in fewer, larger treatments, is as safe and effective at treating early breast cancer as the international standard dose, according to the 10-year follow-up results of a major Cancer Research UK trial presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium today (Thursday). A lower total dose of radiotherapy, delivered in fewer, larger treatments, is as safe and effective at treating early breast cancer as the international standard dose, according to the 10-year follow-up results of a major Cancer Research UK trial presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium today (Thursday).

6 December 2012

• Health & Medicine

Trial reveals 10 years of tamoxifen halves later deaths from commonest kind of cancer

Ten years of tamoxifen treatment can approximately halve the number of deaths from the most common form of breast cancer during the second decade after diagnosis, according to the results of the Cancer Research UK- funded ATLAS trial published in the Lancet today. Ten years of tamoxifen treatment can approximately halve the number of deaths from the most common form of breast cancer during the second decade after diagnosis, according to the results of the Cancer Research UK- funded ATLAS trial published in the Lancet today.

5 December 2012

‘Chemical jobs’ – should women be worried?

22 November 2012

• Science & Technology
• Health & Medicine

Notes from the NCRI conference (day 3)

6 November 2012

• Health & Medicine

Smokers leave a history of their addiction in DNA

Smokers are leaving a history of addiction in their DNA that may help to measure their risk of cancer, according to research presented at the NCRI Cancer Conference today. Smokers are leaving a history of addiction in their DNA that may help to measure their risk of cancer, according to research presented at the NCRI Cancer Conference today.

6 November 2012

• Health & Medicine

Three-in-one 'supermolecule' could detect cancer early, help destroy tumours and monitor treatment

The same protein could potentially be targeted to detect precancerous breast cells; deliver radiotherapy to destroy tumours; and monitor the effectiveness of treatment, according to a Cancer Research UK study presented at the NCRI Cancer Conference in Liverpool today. The same protein could potentially be targeted to detect precancerous breast cells; deliver radiotherapy to destroy tumours; and monitor the effectiveness of treatment, according to a Cancer Research UK study presented at the NCRI Cancer Conference in Liverpool today.

6 November 2012

• Science & Technology

Notes from the NCRI conference (day 1)

4 November 2012

Experimental combination therapy trial for breast cancer patients no longer responding to treatment

Cancer Research UK’s Drug Development Office (DDO) has joined forces with academia and industry to trial an experimental drug from AstraZeneca called AZD4547 in combination with existing therapies, to treat post-menopausal women whose breast cancer has spread and is no longer responding to standard treatment. Cancer Research UK’s Drug Development Office (DDO) has joined forces with academia and industry to trial an experimental drug from AstraZeneca called AZD4547 in combination with existing therapies, to treat post-menopausal women whose breast cancer has spread and is no longer responding to standard treatment.

2 November 2012

• Science & Technology
• Health & Medicine

How can we improve the breast cancer screening programme?

In the light of the results of the Independent Breast Screening Review (aka Marmot Review), we look at research to improve breast screening and diagnosis In the light of the results of the Independent Breast Screening Review (aka Marmot Review), we look at research to improve breast screening and diagnosis

30 October 2012

• Health & Medicine

Cancer Research UK's response to the breast screening review

Our official response to the Independent Breast Screening Review Panel's findings Our official response to the Independent Breast Screening Review Panel's findings

30 October 2012